ArticleClinical and molecular hepatology2024

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.

Sun Young Yim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.